B
Beeline MedicinesDrug Discovery
Beeline Medicines uses AI to discover and develop novel drugs faster and more efficiently than traditional methods.
$126.3MSeries A Extension
Investor undisclosed
A $126M Series A extension signals that AI drug discovery has moved past the hype phase—investors are now betting on execution and clinical validation, not just the promise of faster screening. Beeline likely uses this to push candidates through preclinical/early clinical stages and prove the AI model actually reduces time-to-IND. If you're building in adjacent biotech infrastructure (lab automation, data platforms, regulatory tech), this validates that deep-pocketed founders will pay for tools that compress the discovery bottleneck.